European approval of the PRIMA system could allow patients with advanced macular degeneration to recover functional central vision through a combination of a tiny eye implant and camera-equipped glasses
A retinal implant capable of restoring limited reading vision to people with severe age-related macular degeneration has received European regulatory approval, marking an important step in the effort to connect biological sight with digital technology.
California-based Science Corporation announced that its PRIMA system had received the European CE mark, allowing the medical device to move towards commercial use across European markets. The first commercial implantation is expected to take place in Germany, while reimbursement applications and specialist clinical sites are being prepared in other countries.
The approval is significant because PRIMA is designed to restore what researchers call “form vision”: the ability to distinguish shapes, letters, numbers and words. Earlier generations of retinal prostheses often produced flashes or patterns of light without providing sufficient resolution for practical reading.
PRIMA does not recreate normal eyesight, nor does it cure the underlying disease. Instead, it offers a technologically generated form of central vision to patients whose natural photoreceptor cells have been destroyed by geographic atrophy, an advanced form of age-related macular degeneration.
The condition damages the macula, the central portion of the retina responsible for detailed vision. Patients may retain peripheral sight but gradually lose the ability to read, recognise faces or clearly see objects directly in front of them.
The PRIMA system attempts to bypass the damaged photoreceptors. A small wireless microchip is surgically placed beneath the retina, in the area affected by the disease. A camera mounted on a pair of specialised glasses captures the patient’s surroundings and converts the images into infrared patterns projected onto the implant.
The chip’s photovoltaic cells transform that light into electrical stimulation. Surviving retinal neurons then transmit the resulting signals through the optic nerve, allowing the brain to interpret a simplified visual image.
In a multicentre clinical study, 84% of participants reported that they could use the system to read letters, numbers or words. Patients experienced an average improvement of more than five lines on a standard vision chart, while researchers reported no significant average deterioration in their remaining natural peripheral vision.
Those results represent functional progress rather than full restoration. The visual information produced by the current device is monochromatic, limited in resolution and concentrated within a relatively narrow field. Patients also require rehabilitation and practice as their brains learn to interpret the artificial signals.
Even with those limitations, recovering the ability to identify text can have a profound effect on independence. Reading labels, recognising numbers, completing puzzles or navigating signs are ordinary activities that become extremely difficult after central vision is lost.
The European authorisation moves the technology beyond the experimental stage and towards routine clinical practice. Science Corporation describes PRIMA as the first brain-computer-interface device to receive a CE mark specifically for restoring form vision.
The term brain-computer interface is more commonly associated with implants placed directly in the brain. PRIMA operates through the retina, but it belongs to the same broader field of neurotechnology: electronic systems that communicate with the nervous system to replace or supplement a lost biological function.
Its development also illustrates how medical research is combining several rapidly advancing technologies. Miniaturised electronics make it possible to implant a wireless device inside the eye. Digital imaging converts the physical world into a signal the implant can process. Neuroscience guides the stimulation of surviving retinal cells, while software can enhance contrast and simplify visual scenes for the user.
Researchers are already studying how machine-learning techniques could improve the representation of complex images. Experimental work has examined algorithms that accentuate facial landmarks and contrast before images are transmitted to the implant, potentially making faces easier for patients to interpret.
Future versions could also use smaller pixels, more advanced image processing and less cumbersome glasses. The current system still requires external computing and power equipment, and improving portability will be important if the technology is to become practical for daily use.
Access may prove to be as important as technical performance. Retinal implantation requires specialist surgery, follow-up care and visual rehabilitation. The price of the device and the willingness of national health systems or insurers to reimburse treatment will determine how many eligible patients can benefit.
Regulatory approval also does not eliminate the medical risks associated with implant surgery. Patients and clinicians must weigh the possibility of complications against the potential improvement in functional sight. Longer-term monitoring will be necessary to establish how well the implant performs over many years.
Science Corporation is also pursuing entry into the United States. The PRIMA system has received a humanitarian-use-device designation from the U.S. Food and Drug Administration, an important regulatory step for devices intended to treat relatively small patient populations with serious conditions.
The company was founded by Max Hodak, a former co-founder of Neuralink, and has broader ambitions in brain-computer interfaces and biologically integrated electronics. Unlike many neurotechnology projects that remain in early laboratory or clinical stages, PRIMA now offers a potential route to commercial revenue and real-world patient use.
Its approval does not mean that blindness has been solved. The system is intended for a particular form of central retinal degeneration and will not be suitable for every cause of vision loss. The images it provides remain fundamentally different from natural sight.
Nevertheless, the development demonstrates that an electronic implant can return a medically useful visual function after the eye’s light-detecting cells have been permanently damaged.
For decades, the idea of a “bionic eye” belonged largely to science fiction or experimental medicine. With PRIMA moving towards its first commercial patients in Europe, artificial vision is beginning to enter clinical reality—not as perfect sight, but as a carefully engineered bridge between a camera, a microchip and the human nervous system.
